Follicular Lymphoma

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Videos

Ten-Year Outcomes With Tisagenlecleucel Demonstrate Durable Remissions in B-Cell Lymphoma

07/01/2026

Marco Ruella, MD

Marco Ruella, MD, discusses 10-year follow-up data showing that tisagenlecleucel produced durable remissions in patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma, supporting the long-term curative...

Marco Ruella, MD, discusses...

07/01/2026

Oncology

Videos

Epcoritamab Improves Outcomes Regardless of Risk Profile in Relapsed Follicular Lymphoma

06/23/2026

Benoit Tessoulin, MD, PhD

Benoit Tessoulin, MD, PhD, discusses subgroup analyses from the phase 3 EPCORE FL-1 trial showing that epcoritamab plus lenalidomide and rituximab provided consistent progression-free survival benefits across all major risk groups in patients...

Benoit Tessoulin, MD, PhD,...

06/23/2026

Oncology

Conference Coverage

Analyzing Patient Preferences on Follicular Lymphoma Treatment Delivery Options

01/16/2026

Krish Patel, MD

Krish Patel, MD, shared results from a patient preference study for relapsed/refractory follicular lymphoma at the 2025 ASH Annual Meeting & Exposition.

Krish Patel, MD, shared results...

01/16/2026

Oncology

Videos

Subcutaneous Mosunetuzumab Demonstrates Deep, Early Responses for Treatment-Naïve Follicular Lymphoma: Phase 2 MorningSun Trial

01/08/2026

John Burke, MD

John Burke, MD, reported that subcutaneous mosunetuzumab achieved high response rates and durable remissions with manageable toxicity for treatment-naïve, high-tumor burden follicular lymphoma.

John Burke, MD, reported that...

01/08/2026

Oncology

Videos

Five-Year Data Show Durable Remissions With Tisagenlecleucel for R/R Follicular Lymphoma: ELARA Trial

01/08/2026

Stephen Schuster, MD

Stephen Schuster presented updated results from the phase 2 ELARA study which evaluated tisagenlecleucel among patients with relapsed/refractory follicular lymphoma.

Stephen Schuster presented...

01/08/2026

Oncology

Conference Coverage

Lisocabtagene Maraleucel Achieves High Responses and Durable 3-Year Remissions for R/R Follicular Lymphoma: TRANSCEND FL

12/07/2025

Sairah Ahmed, MD

For patients with at least 3 prior lines of therapy, lisocabtagene maraleucel produced durable, high response rates among patients with R/R follicular lymphoma, according to a 3-year update presented at the 2025 ASH Annual Meeting.

For patients with at least 3...

12/07/2025

Oncology

Videos

Emerging Targeted Therapies for Peripheral T-Cell Lymphoma

11/06/2025

Jia Ruan, MD, PhD

Jia Ruan, MD, shares insights into novel targeted therapies for patients with peripheral T-cell lymphoma at the 2025 Lymphoma, Leukemia, & Myeloma Congress.

Jia Ruan, MD, shares insights...

11/06/2025

Oncology

Videos

Emerging Treatments for Patients With Relapsed/Refractory Follicular Lymphoma

10/16/2025

Erin Mulvey, MD

Erin Mulvey, MD, discusses novel treatment options for patients with relapsed/refractory follicular lymphoma at the 2025 Lymphoma, Leukemia & Myeloma Congress.

Erin Mulvey, MD, discusses novel...

10/16/2025

Oncology

Videos

Strategies for Frontline Follicular Lymphoma Treatment and Curative Potential

10/15/2025

Emily Estrada

Jonathan Friedberg, MD, reviews recent clinical trial data and discusses strategies and progress in the treatment of patients with follicular lymphoma at the 2025 Lymphoma, Leukemia & Myeloma Congress.

Jonathan Friedberg, MD, reviews...

10/15/2025

Oncology

Videos

Analyzing the Benefits of Circulating Tumor DNA Testing for Patients With Lymphoma

10/15/2025

David Russler-Germain, MD, PhD

David Russler-Germain, MD, PhD, shares insights into the advantages of using circulating tumor DNA testing for patients with lymphoma to optimize patient care through genetic profiling and accurate disease activity testing.

David Russler-Germain, MD, PhD,...

10/15/2025

Oncology

Recent News

Commentary

Challenges of Managing FL: A Focus on PI3K Inhibitors and Next-Line Therapy

04/26/2020

Elizabeth Brem, MD, discusses some of the challenges with managing FL, focusing on the incorporation of PIK3 kinase inhibitors in the treatment of these patients.

Elizabeth Brem, MD, discusses...

04/26/2020

Oncology

FDA Approval

FDA Approves Pegfilgrastim Biosimilar ENNUMO for the Prevention of Febrile Neutropenia and Treatment of Acute Radiation Syndrome

07/13/2026

Stephanie Holland

The FDA approved ENNUMO, a biosimilar to pegfilgrastim, for the same indications as the reference product, providing an additional granulocyte colony-stimulating factor option to reduce febrile neutropenia during myelosuppressive chemotherapy...

The FDA approved ENNUMO, a...

07/13/2026

Oncology

FDA Alerts

FDA Accepts New Drug Application for Mezigdomide Combination in Relapsed or Refractory Multiple Myeloma

07/13/2026

Stephanie Holland

The FDA accepted the new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed or refractory multiple myeloma based on phase 3 SUCCESSOR-2 results demonstrating a significant progression-free survival benefit...

The FDA accepted the new drug...

07/13/2026

Oncology

News

Trastuzumab Rezetecan Improves Progression-Free Survival in Previously Treated HER2-Positive Metastatic Breast Cancer

07/10/2026

Stephanie Holland

Interim results from the phase 3 HORIZON-Breast01 trial demonstrated that trastuzumab rezetecan significantly improved progression-free survival compared with pyrotinib plus capecitabine in patients with previously treated HER2-positive...

Interim results from the phase...

07/10/2026

Oncology

FDA Approval

FDA Approves Subcutaneous Isatuximab Across Multiple Indications for Patients With Multiple Myeloma

07/10/2026

Emily Estrada

The FDA has approved subcutaneous isatuximab for three treatment indications in multiple myeloma, including in combination with pomalidomide and dexamethasone, carfilzomib and dexamethasone, or bortezomib, lenalidomide, and dexamethasone.

The FDA has approved...

07/10/2026

Oncology

News

Performance Status Predicts Real-World Outcomes With Tarlatamab in Extensive-Stage Small Cell Lung Cancer

07/09/2026

Stephanie Holland

A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...

A multicenter real-world study...

07/09/2026

Oncology

News

Adjuvant Ensartinib Demonstrates Significant Disease-Free Survival Benefit in ALK-Positive Non-Small Cell Lung Cancer

07/09/2026

Stephanie Holland

Results from the phase 3 ELEVATE trial demonstrated that adjuvant ensartinib significantly improved disease-free survival compared with placebo in patients with completely resected ALK-positive non-small cell lung cancer, supporting its use...

Results from the phase 3 ELEVATE...

07/09/2026

Oncology

FDA Alerts

FDA Accepts New Drug Application for Varegacestat in Adult Patients With Progressing Desmoid Tumors

07/09/2026

Emily Estrada

The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...

The FDA accepted the new drug...

07/09/2026

Oncology

News

Brain Radiotherapy Plus Continued Systemic Therapy Improves Survival in Brain-Only Progressive Extensive-Stage Small Cell Lung Cancer

07/09/2026

Stephanie Holland

Results from a multicenter cohort study demonstrated that continuing the original systemic therapy plus brain radiotherapy improved survival in patients with extensive-stage small cell lung cancer who developed brain-only progression after...

Results from a multicenter...

07/09/2026

Oncology

News

Dose-Escalation Study Supports Phase 2 Development of BMS-986205 Plus Radiotherapy and Nivolumab in Glioblastoma

07/09/2026

Stephanie Holland

Results from a phase 1 trial demonstrated that radiotherapy plus nivolumab and the IDO1 inhibitor BMS-986205 was generally well tolerated in patients with newly diagnosed IDH-wild-type glioblastoma, establishing a recommended phase 2 dose for...

Results from a phase 1 trial...

07/09/2026

Oncology

News

First-in-Class Hepcidin Inhibitor DISC-0974 Demonstrates Activity in Myelofibrosis-Associated Anemia

07/09/2026

Stephanie Holland

Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...

Results from the ongoing, phase...

07/09/2026

Oncology